Abstract
BackgroundInfliximab is a chimeric anti-tumour necrosis factor-alpha (anti-TNFa) monoclonal antibody that has been used safely in the management of Inflammatory Bowel Disease (IBD) for over 20 years, recommended for use...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
